{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:23:06Z","timestamp":1789237386619,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015087","name":"Markey Cancer Center, University of Kentucky","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015087","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA177558"],"award-info":[{"award-number":["P30 CA177558"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA264652"],"award-info":[{"award-number":["R01 CA264652"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA256893"],"award-info":[{"award-number":["R01 CA256893"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA272483"],"award-info":[{"award-number":["R01 CA272483"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA157429"],"award-info":[{"award-number":["R01 CA157429"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1124\/jpet.124.002424","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T17:10:42Z","timestamp":1728407442000},"page":"100034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Metformin in overcoming enzalutamide resistance in castration-resistant prostate cancer"],"prefix":"10.1016","volume":"392","author":[{"given":"Kendall","family":"Simpson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek B.","family":"Allison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.124.002424_bib1","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/327253","article-title":"Castration-resistant prostate cancer: mechanisms, targets, and treatment","volume":"2012","author":"Amaral","year":"2012","journal-title":"Prostate Cancer"},{"key":"10.1124\/jpet.124.002424_bib2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1124\/jpet.124.002424_bib3","doi-asserted-by":"crossref","first-page":"9911","DOI":"10.1074\/jbc.RA119.008152","article-title":"Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer","volume":"294","author":"Bai","year":"2019","journal-title":"J\u00a0Biol Chem"},{"key":"10.1124\/jpet.124.002424_bib4","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","article-title":"The antidiabetic drug metformin exerts an antitumoral effect in\u00a0vitro and in\u00a0vivo through a decrease of cyclin D1 level","volume":"27","author":"Ben Sahra","year":"2008","journal-title":"Oncogene"},{"key":"10.1124\/jpet.124.002424_bib5","first-page":"93","article-title":"What is synergy?","volume":"41","author":"Berenbaum","year":"1989","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.124.002424_bib6","first-page":"365","article-title":"Mechanisms of resistance in castration-resistant prostate cancer (CRPC)","volume":"4","author":"Chandrasekar","year":"2015","journal-title":"Transl Androl Urol"},{"key":"10.1124\/jpet.124.002424_bib7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1080\/15384101.2016.1151582","article-title":"Combining p53 stabilizers with metformin induces synergistic apoptosis through regulation of energy metabolism in castration-resistant prostate cancer","volume":"15","author":"Chen","year":"2016","journal-title":"Cell Cycle"},{"key":"10.1124\/jpet.124.002424_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fphys.2017.00097","article-title":"Glucose metabolism in the progression of prostate cancer","volume":"8","author":"Cutruzzol\u00e0","year":"2017","journal-title":"Front Physiol"},{"key":"10.1124\/jpet.124.002424_bib9","doi-asserted-by":"crossref","first-page":"378","DOI":"10.4103\/1008-682X.122876","article-title":"PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance","volume":"16","author":"Edlind","year":"2014","journal-title":"Asian J Androl"},{"key":"10.1124\/jpet.124.002424_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2014.05.005","article-title":"Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer","volume":"67","author":"Efstathiou","year":"2015","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.124.002424_bib11","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1158\/1535-7163.MCT-21-0581","article-title":"Targeting DNMTs to overcome enzalutamide resistance in prostate cancer","volume":"21","author":"Farah","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.124.002424_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.drudis.2007.12.008","article-title":"Advances in measuring cellular bioenergetics using extracellular flux","volume":"13","author":"Ferrick","year":"2008","journal-title":"Drug Discov Today"},{"key":"10.1124\/jpet.124.002424_bib13","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/gerona\/glr263","article-title":"Review: quantifying mitochondrial dysfunction in complex diseases of aging","volume":"67","author":"Horan","year":"2012","journal-title":"J\u00a0Gerontol A Biol Sci Med Sci"},{"key":"10.1124\/jpet.124.002424_bib14","doi-asserted-by":"crossref","first-page":"10499","DOI":"10.2147\/OTT.S266085","article-title":"Novel therapeutic strategies for CDK4\/6 inhibitors in metastatic castrate-resistant prostate cancer","volume":"13","author":"Kase","year":"2020","journal-title":"Onco Targets Ther"},{"key":"10.1124\/jpet.124.002424_bib15","first-page":"57","article-title":"Metformin in cancer prevention and therapy","volume":"2","author":"Kasznicki","year":"2014","journal-title":"Ann Transl Med"},{"key":"10.1124\/jpet.124.002424_bib16","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1158\/1535-7163.MCT-19-0874","article-title":"Inhibition of EZH2 enhances the antitumor efficacy of metformin in prostate cancer","volume":"19","author":"Kong","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/jpet.124.002424_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.neo.2019.12.003","article-title":"Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment","volume":"22","author":"Kregel","year":"2020","journal-title":"Neoplasia"},{"key":"10.1124\/jpet.124.002424_bib18","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1038\/s41388-022-02444-1","article-title":"GSTM2 is a key molecular determinant of resistance to SG-ARIs","volume":"41","author":"Li","year":"2022","journal-title":"Oncogene"},{"key":"10.1124\/jpet.124.002424_bib19","article-title":"A\u00a0kinome-wide CRISPR screen identifies CK1alpha as a target to overcome enzalutamide resistance of prostate cancer","volume":"4","author":"Liu","year":"2023","journal-title":"Cell Rep Med"},{"key":"10.1124\/jpet.124.002424_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.417","article-title":"Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-beta1\/STAT3 axis-regulated EMT","volume":"8","author":"Liu","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1124\/jpet.124.002424_bib21","article-title":"Measurement and analysis of extracellular acid production to determine glycolytic rate","volume":"106","author":"Mookerjee","year":"2015","journal-title":"J\u00a0Vis Exp"},{"key":"10.1124\/jpet.124.002424_bib22","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1093\/aje\/kwn190","article-title":"Antidiabetic medication and prostate cancer risk: a population-based case-control study","volume":"168","author":"Murtola","year":"2008","journal-title":"Am J Epidemiol"},{"key":"10.1124\/jpet.124.002424_bib23","article-title":"MAP kinases and prostate cancer","volume":"2012","author":"Rodr\u00edguez-Berriguete","year":"2012","journal-title":"J\u00a0Signal Transduct"},{"key":"10.1124\/jpet.124.002424_bib24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.eururo.2013.12.057","article-title":"Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08\/09)","volume":"66","author":"Rothermundt","year":"2014","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.124.002424_bib25","doi-asserted-by":"crossref","first-page":"63065","DOI":"10.18632\/oncotarget.11757","article-title":"Targeted suppression of AR-V7 using PIP5K1alpha inhibitor overcomes enzalutamide resistance in prostate cancer cells","volume":"7","author":"Sarwar","year":"2016","journal-title":"Oncotarget"},{"key":"10.1124\/jpet.124.002424_bib26","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrclinonc.2010.136","article-title":"Drug resistance in metastatic castration-resistant prostate cancer","volume":"8","author":"Seruga","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1124\/jpet.124.002424_bib27","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1074\/jbc.M114.596817","article-title":"Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer","volume":"290","author":"Shao","year":"2015","journal-title":"J\u00a0Biol Chem"},{"key":"10.1124\/jpet.124.002424_bib28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","article-title":"Androgen deprivation therapy for prostate cancer","volume":"294","author":"Sharifi","year":"2005","journal-title":"JAMA"},{"key":"10.1124\/jpet.124.002424_bib29","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMsb2000250","article-title":"Reconsidering the trade-offs of prostate cancer screening","volume":"382","author":"Shoag","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1124\/jpet.124.002424_bib30","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.124.002424_bib31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1124\/jpet.124.002424_bib32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharmacol Res"},{"key":"10.1124\/jpet.124.002424_bib33","doi-asserted-by":"crossref","first-page":"5515","DOI":"10.3390\/ijms22115515","article-title":"AR-V7 in metastatic prostate cancer: a strategy beyond redemption","volume":"22","author":"Sobhani","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1124\/jpet.124.002424_bib34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.eururo.2012.12.004","article-title":"Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality","volume":"63","author":"Spratt","year":"2013","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.124.002424_bib35","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.cmet.2015.11.002","article-title":"Mitochondrial membrane potential identifies cells with enhanced stemness for cellular therapy","volume":"23","author":"Sukumar","year":"2016","journal-title":"Cell Metab"},{"key":"10.1124\/jpet.124.002424_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1159557","article-title":"PARP inhibitors in metastatic prostate cancer","volume":"13","author":"Taylor","year":"2023","journal-title":"Front Oncol"},{"key":"10.1124\/jpet.124.002424_bib37","first-page":"600","article-title":"Administration of substances to laboratory animals: routes of administration and factors to consider","volume":"50","author":"Turner","year":"2011","journal-title":"J\u00a0Am Assoc Lab Anim Sci"},{"key":"10.1124\/jpet.124.002424_bib38","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.eururo.2014.11.033","article-title":"Targeting the androgen receptor confers in\u00a0vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer","volume":"67","author":"van Soest","year":"2015","journal-title":"Eur Urol"},{"key":"10.1124\/jpet.124.002424_bib39","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bph.15300","article-title":"Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it","volume":"178","author":"Wang","year":"2021","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.124.002424_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/jcb.10683","article-title":"Ras signaling in prostate cancer progression","volume":"91","author":"Weber","year":"2004","journal-title":"J\u00a0Cell Biochem"},{"key":"10.1124\/jpet.124.002424_bib41","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.bbabio.2012.02.033","article-title":"Bioenergetic role of mitochondrial fusion and fission","volume":"1817","author":"Westermann","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/jpet.124.002424_bib42","first-page":"4277","article-title":"Combination of metformin and paclitaxel suppresses proliferation and induces apoptosis of human prostate cancer cells via oxidative stress and targeting the mitochondria-dependent pathway","volume":"17","author":"Zhao","year":"2019","journal-title":"Oncol Lett"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524000922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524000922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.124.002424","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T23:10:55Z","timestamp":1738278655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524000922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0022356524000922"],"URL":"https:\/\/doi.org\/10.1124\/jpet.124.002424","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin in overcoming enzalutamide resistance in castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.124.002424","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100034"}}